© 2024 MJH Life Sciences™ and Patient Care Online. All rights reserved.
Grace Halsey
Articles
IDWeek 2023: Nirsevimab Efficacy Against RSV-LRTI-Associated Hospitalization is Robust Across Infant Subgroups
October 15, 2023
IDWeek 2023. Nirsevimab efficacy was significant across infant subgroups in preventing hospitalization for RSV-LRTI during a first RSV season.
IDWeek 2023: Social Determinants of RSV Hospitalization in Older Adults
October 15, 2023
IDWeek 2023: Older adults hospitalized with respiratory syncytial virus were more likely to be women, be immunocompromised, and to have traveled within the prior 2 weeks,
Investigational mRNA CMV Vaccine Ready for Phase 3 Clinical Trial, Based on Results of Phase 2 Safety, Efficacy and Dose-Finding Study
October 14, 2023
The phase 2 study found that nAB responses against epithelial cell infection were strong after each mRNA-1647 dose and sustained through 12 months.
IDWeek 2023 Late Breaker: Efficacy of Single RSVPreF3 Dose Sustained Over 2 Seasons in High-Risk Older Adults
October 14, 2023
A phase 3 study found VE from a single shot against RSV-LRTD in adults aged ≥60 years persisted through a second season; revaccination did not increase protection.
Pfizer Maternal RSV Vaccine Could Reduce Infant Clinical Events by Tens of Thousands, Costs by $800 Million
October 14, 2023
A modeling study projected an annual reduction of nearly 25 000 infant hospitalizations and 46 000 ED encounters following maternal vaccination against RSV.
Coadministration of RSV, Influenza Vaccines is Safe and Effective in Older Adults, Study Finds
October 14, 2023
Immune response in older adults after receiving both vaccines in the same visit was noninferior to sequential administration and the safety profile was acceptable.
Late-Breaker: COVID-19 mRNA-1273 Booster Most Effective Among Adults Aged 65 and Older During Delta, Omicron Surges
October 13, 2023
The study findings on enhanced immunity from a third mRNA-1273 dose and specific population benefits will help build effective public health policy, authors say.
Breaking: Novel Live-Attenuated Intranasal COVID-19 Vaccine Yields Significant Humoral, Cellular Immune Response
October 13, 2023
The intranasal delivery and live attenuated form of CoviLiv may strengthen immune response and vaccine acceptance and uptake in populations and regions where both are low.
Novo Stops Semaglutide Kidney Outcomes Trial Early for Efficacy
October 11, 2023
The phase 3 semaglutide kidney outcomes trial will be stopped immediately with FLOW read out expected in early 2024, the company said.
In People Living with HIV, Switch from Oral ART to Long-Acting Injectable Significantly Improved Adherence, Persistence
October 11, 2023
IDWeek 2023: In a large cohort of people living with HIV, those switching from oral ART to long acting CAB+RPV were more than 4x as likely to adhere to the regimen.